Clinical trials: Digestive Disorders
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Gastroesophageal Reflux Disease
Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease
BACKGROUND: Gastroesophageal reflux disease is a very frequent clinical condition and nocturnal symptoms are a cause of quality of life impairment, poor sleep quality and absenteeism.
- Trial name
- IBELGA (NCT02706938)
- Testing
- Head of bed elevation, Standard treatment
- Where
- Colombia
- Volunteers
- 65 people
- Sponsor
- Universidad Nacional de Colombia
Head and Neck Cancer, Stroke
Real-Time Internet Evaluation of Swallowing
The purpose of this study is to determine whether real-time internet evaluations of swallowing, or x-ray swallow studies viewed over closed internet circuit, are a reliable method of evaluating swallowing function.
- Trial name
- NCT00580138
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Arkansas
Hepatitis C Virus (HCV)
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
This study evaluates the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with hepatitis C virus (HCV) genotype 1a (GT1a) or genotype 4 (GT4) infection and with severe kidney impairment…
- Trial name
- NCT02487199
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir
- Volunteers
- 18 people
- Sponsor
- AbbVie
Fatty Liver, Surgery
Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
The purpose of this study is to objectively quantify liver fat content (LFC) by Magnetic Resonant Imaging (MRI) prior to major liver surgery, and to investigate its association with post-operative complications.
- Trial name
- MRsteatosis (NCT01234714)
- Testing
- Non-invasive Magnetic Resonance Imaging (MRI), Major liver resection
- Where
- 2 sites in Switzerland
- Volunteers
- 84 people
- Sponsor
- University of Zurich
Chronic Hepatitis C
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV)…
- Trial name
- NCT01625338
- Testing
- SOF, RBV, Peg-IFN
- Where
- 175 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Gilead Sciences
Hepatitis C
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV)…
- Trial name
- NCT01500772
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 6 people
- Sponsor
- Debiopharm International SA
Nonalcoholic Steatohepatitis
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
- Trial name
- CENTAUR (NCT02217475)
- Testing
- Cenicriviroc
- Where
- 91 sites in United States, Australia and 8 more
- Volunteers
- 289 people
- Sponsor
- Tobira Therapeutics, Inc.
Crohn's Disease
Open-Label Extension Study of GSK1605786A
An open-label study to evaluate the safety and effectiveness of GSK1605786A 500 mg twice daily over 108 weeks in adult subjects with Crohn's disease.
- Trial name
- SHIELD-3 (NCT01318993)
- Testing
- GSK1605786A
- Where
- 244 sites in United States, Australia and 29 more
- Volunteers
- 399 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Metastatic
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
This is a single center, open label dose frequency escalation study of CryoVax®. personalized anti-tumor vaccine protocol combining the cryoablation of a selected metastatic lesion with intra-lesional immunotherapy with…
- Trial name
- NCT02380443
- Testing
- AlloStim, Cryoablation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mirror Biologics, Inc.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).
- Trial name
- TOGAR (NCT05567835)
- Testing
- Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK…
- Trial name
- HI (NCT02891408)
- Testing
- Firsocostat, Fenofibrate
- Where
- 5 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Mitral Valve (MV) Regurgitation
ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
The MitraClip System enables the European physicians an alternative therapeutic option for patients with mitral regurgitation (MR).
- Trial name
- ACCESS-EU (NCT01288976)
- Testing
- MitraClip, Medical Management, Mitral Valve Surgery
- Where
- Germany
- Volunteers
- 721 people
- Sponsor
- Abbott Medical Devices
Eating Disorders
Leveraging Social Media to Identify and Connect Teens With Eating Disorders to a Mobile Guided Self-Help Mobile Intervention
Clinical or subclinical eating disorders (EDs) impact 10% of individuals in their lifetime and are marked by significant functional impairment, early mortality, chronicity, and emotional distress.
- Trial name
- NCT04636840
- Testing
- Space From Body and Eating Concerns- Teen
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Washington University School of Medicine
Hepatitis C, Cirrhosis
Intravenous Interferon During Liver Transplant
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation.
- Trial name
- NCT01192698
- Testing
- IV interferon
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome
Cholestasis Reversal: Efficacy of IV Fish Oil
The purpose of this study is to determine whether Omegaven is effective in the treatment of parenteral nutrition associated liver disease (PNALD).
- Conditions
- Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease
- Trial name
- Reversal (NCT00910104)
- Testing
- Omegaven®
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mark Puder
Hepatocellular Carcinoma
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular…
- Trial name
- NCT02013778
- Testing
- HCQ
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Nutritional and Metabolic Diseases
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
The purpose of this study is to identify metabolic signatures associated with malodor conditions. The investigators will perform state-of-the art metabolomics tests and bioinformatic data mining to explore if conditions leading…
- Trial name
- NCT02683876
- Where
- 2 sites in United States, Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Mebo Research, Inc.
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00033540
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 112 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network